Core Viewpoint - Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is identified as a strong investment opportunity with significant upside potential, supported by positive analyst ratings and promising clinical trial results [1][2][4]. Group 1: Analyst Ratings and Price Targets - All eleven analysts covering Lexeo Therapeutics have a consensus buy rating, with a median price target of $19, indicating an upside potential of 79.92% from current levels [1]. - Raymond James initiated coverage with a 'Strong Buy' rating and a price target of $25, based on solid results from clinical trials and favorable FDA feedback [2]. - Cantor Fitzgerald reaffirmed an 'Overweight' rating with a price target of $19, also suggesting an upside potential of around 80% driven by the company's PKP2-ACM program [4]. Group 2: Clinical Trials and Revenue Projections - The lead candidate, LX2006, is an AAV gene therapy for cardiomyopathy associated with Friedreich's Ataxia, which is considered well-positioned for success in its pivotal trial [2]. - Raymond James anticipates LX2006 revenue of $14.1 million in FY27, potentially increasing to $805.3 million by FY32 [3]. Group 3: Company Overview - Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company based in New York, founded in 2017, with a pipeline that includes LX2006, LX2020, and LX2021 [5].
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline